Karen K. McGinnis has served as a Director since June 2019. Ms. McGinnis has over 30 years of experience, including serving in executive operational and finance roles at international public companies. In April 2021, Ms. McGinnis retired from Illumina, Inc., a leader in sequencing- and array-based solutions for genetic and genomic analysis, where she served as Chief Accounting Officer since November 2017. She also currently serves on the boards of Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, and iRhythm Technologies, Inc. (Nasdaq: IRTC), a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. She previously served on the boards of Sonendo, Inc. (NYSE: SONX), a medical technology company focused on saving teeth from tooth decay and Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. Prior to joining Illumina in November 2017, Ms. McGinnis served from February 2016 to April 2017 as Director, President and Chief Executive Officer of Mad Catz Interactive, Inc. a global provider of innovative interactive entertainment products. From June 2013 through February 2016, Ms. McGinnis served as Mad Catz’ Chief Financial Officer. Prior to joining Mad Catz, Ms. McGinnis served from November 2009 through May 2013 as Chief Accounting Officer of Cymer, Inc., the world’s leading supplier of light sources used in the photolithography process for semiconductor or chip manufacturing until its acquisition in 2013. Ms. McGinnis also served as Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. McGinnis is a Certified Public Accountant and earned her BBA in Accounting from the University of Oklahoma.
What is Karen K. McGinnis' net worth?
The estimated net worth of Karen K. McGinnis is at least $784.82 thousand as of June 11th, 2026. Ms. McGinnis owns 94,671 shares of Alphatec stock worth more than $784,823 as of June 16th. This net worth approximation does not reflect any other investments that Ms. McGinnis may own. Learn More about Karen K. McGinnis' net worth.
How do I contact Karen K. McGinnis?
Has Karen K. McGinnis been buying or selling shares of Alphatec?
During the last ninety days, Karen K. McGinnis has sold $48,460.50 of Alphatec stock. Most recently, Karen K. Mcginnis sold 6,050 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $8.01, for a transaction totalling $48,460.50. Following the completion of the sale, the director now directly owns 94,671 shares of the company's stock, valued at $758,314.71. Learn More on Karen K. McGinnis' trading history.
Who are Alphatec's active insiders?
Alphatec's insider roster includes Evan Bakst (Director), Jeffrey Black (CFO), David Demski (Director), Jason Hochberg (Director), Craig Hunsaker (EVP), Mortimer III (Director), John Koning (Chief Financial Officer), Scott Lish (SVP), Tyson Marshall (General Counsel & Corporate Secretary), Karen McGinnis (Director), Patrick Miles (CEO), David Mowry (Director), David Pelizzon (Director), Jennifer Pritzker (Major Shareholder), Jeffrey Rydin (Director), Paul Segal (Major Shareholder), David Sponsel (EVP), and James Tullis (Director). Learn More on Alphatec's active insiders.
Are insiders buying or selling shares of Alphatec?
In the last twelve months, insiders at the medical technology company sold shares 52 times. They sold a total of 4,922,421 shares worth more than $90,884,538.16. The most recent insider tranaction occured on June, 11th when Director Karen K Mcginnis sold 6,050 shares worth more than $48,460.50. Insiders at Alphatec own 13.5% of the company.
Learn More about insider trades at Alphatec. Information on this page was last updated on 6/11/2026.
